AR and prostate cancer: Emerging data from metastatic biopsies of patients with metastatic castration-resistant prostate cancer (CRPC) suggest that up to 15% of patients develop neuroendocrine prostate cancer (NEPC) in later stages of prostate cancer, and this is higher after potent androgen receptor (AR)-targeting therapies (1–5).